Clinical trial news

lab Discussion

PTC Therapeutics, Inc. announced that their collaborative program with Roche and the SMA Foundation (SMAF) for Spinal Muscular Atrophy (SMA) has begun its second phase with adult and children patients, as part of the Phase 1b/2a study. The program is evaluating the safety and tolerability of an under-investigation drug – survival of…

SMA and breathing Discussion

Encouraging news from Isis Pharmaceuticals, Inc., presented at the 19th International World Muscle Society Congress in Berlin, demonstrated the efficacy of ISIS-SMNRx in treating spinal muscular atrophy (SMA) in infants and children. Results were from the ongoing open-label Phase 2 clinical trial. Isis is also enrolling patients in the…

This is a clinical research trial targeting the Type 1 Spinal Muscular Atrophy (SMA) patient population. Center for Gene Therapy The Research Institute at Nationwide Children’s Hospital 700 Children’s Drive Columbus, OH 43205 Principal Investigator: Jerry R Mendell, M.D. Please complete the information request form and you will…